Patents Assigned to PRECIGEN, INC.
-
Publication number: 20220064609Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.Type: ApplicationFiled: June 11, 2021Publication date: March 3, 2022Applicant: PRECIGEN, INC.Inventors: Rutul SHAH, Peter EMTAGE, Ramya YARLAGADDA
-
Publication number: 20220064677Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 1,4-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 1,4-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.Type: ApplicationFiled: September 13, 2021Publication date: March 3, 2022Applicant: PRECIGEN, INC.Inventors: Xinhua ZHAO, Tina HUYNH, Jeffrey ORTH, Lily Yuin CHAO, James KEALEY
-
Publication number: 20220049259Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 2,3-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 2,3-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.Type: ApplicationFiled: July 31, 2021Publication date: February 17, 2022Applicant: PRECIGEN, INC.Inventors: Xinhua ZHAO, Mark Anton HELD, Tina HUYNH, Lily Yuin CHAO, Na TRINH, Matthias Helmut SCHMALISCH, Bryan YEH, James KEALEY, Kevin Lee DIETZEL
-
Publication number: 20220023420Abstract: A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-? trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.Type: ApplicationFiled: July 9, 2021Publication date: January 27, 2022Applicant: Precigen, Inc.Inventors: Helen SABZEVARI, Simon METENOU, Chang Hung CHEN, Rutul SHAH
-
Publication number: 20210395773Abstract: Disclosed herein are improved methods for treatment of brain cancer (such as glioma/glioblastoma) via ligand-inducible gene-switch controlled in vivo expression of an immunomodulator (i.e., IL-12) in combination with one or more other immunomodulators (i.e., an immune cell check point inhibitor; e.g., such as a PD-1 inhibitor or a PD-1 binder.Type: ApplicationFiled: June 27, 2019Publication date: December 23, 2021Applicant: PRECIGEN, INC.Inventors: John Andrew BARRETT, Francois LEBEL
-
Patent number: 11198877Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 2,3-BDO; 1,4-BDO; isobutyraldehyde; isobutanol; 1-butanol; n-butanol; ethanol; fatty alcohols; and fatty acid methyl ester are disclosed. For example, genetically modified methanotrophs that are capable of generating 2,3-BDO; 1,4-BDO; isobutyraldehyde; isobutanol; 1-butanol; n-butanol; ethanol; fatty alcohols; and fatty acid methyl ester at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed. These microorganisms and methods make use of molecular switches to regulate gene expression.Type: GrantFiled: January 30, 2018Date of Patent: December 14, 2021Assignee: PRECIGEN, INC.Inventors: Mark Anton Held, Xinhua Zhao, Lily Yuin Chao, Na Trinh, James Kealey, Kevin Lee Dietzel
-
Patent number: 11155837Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 1,4-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 1,4-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.Type: GrantFiled: March 13, 2018Date of Patent: October 26, 2021Assignee: PRECIGEN, INC.Inventors: Xinhua Zhao, Tina Huynh, Jeffrey Orth, Lily Yuin Chao, James Kealey
-
Patent number: 11154622Abstract: The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.Type: GrantFiled: May 11, 2018Date of Patent: October 26, 2021Assignee: PRECIGEN, INC.Inventors: Dimki S. Patel, Amit N. Patel
-
Publication number: 20210324350Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.Type: ApplicationFiled: May 5, 2021Publication date: October 21, 2021Applicant: PRECIGEN, INC.Inventors: Rutul SHAH, Peter EMTAGE, Ramya YARLAGADDA
-
Patent number: 11118168Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.Type: GrantFiled: June 6, 2018Date of Patent: September 14, 2021Assignee: PRECIGEN, INC.Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
-
Patent number: 11116852Abstract: The invention provides polynucleotides, vectors and viruses expressing frataxin and methods of treating Friedreich's Ataxia.Type: GrantFiled: November 8, 2017Date of Patent: September 14, 2021Assignee: PRECIGEN, INC.Inventors: Stephen Schauer, Darby Thomas, Gregory Robinson, Mark Pykett, Richard Thorn, Kirsten Gruis
-
Patent number: 11111496Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 2,3-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 2,3-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.Type: GrantFiled: January 30, 2018Date of Patent: September 7, 2021Assignee: PRECIGEN, INC.Inventors: Xinhua Zhao, Mark Anton Held, Tina Huynh, Lily Yuin Chao, Na Trinh, Matthias Helmut Schmalisch, Bryan Yeh, James Kealey, Kevin Lee Dietzel
-
Patent number: 11034940Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.Type: GrantFiled: June 6, 2018Date of Patent: June 15, 2021Assignee: PRECIGEN, INC.Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
-
Publication number: 20210139837Abstract: Electroporation is a technique in which an electrical field is applied to cells in order to increase the permeability of the cell membrane. This allows for chemicals, drugs, and/or macromolecules such as proteins and nucleic acids to be introduced into the cells. Embodiments relate to an electroporation apparatus. The electroporation apparatus comprises: a plurality of chambers configured to store a plurality of cells during an electroporation process; a plurality of electrodes configured to generate a plurality of electric fields within the plurality of chambers during the electroporation process, each electric field of the plurality of electric fields corresponding to one chamber of the plurality of chambers; a flow channel configured to transport the plurality cells during a cell collection process after the electroporation process; and a plurality of valves connecting the plurality of chambers to the flow channel.Type: ApplicationFiled: November 11, 2020Publication date: May 13, 2021Applicant: Precigen, Inc.Inventors: Shuyuan ZHANG, Bryan BUTMAN, Justin INSLEE, Robert SCHNEIDER, Kraig KRUGER, Travis ANDREWS, William HOCK, David CERRONE, Scott SCHMIDT, Jeffrey GENTRY, Mackenzie MILLER, Vincent SO, Chad B. GREEN
-
Publication number: 20210024586Abstract: Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.Type: ApplicationFiled: March 6, 2019Publication date: January 28, 2021Applicants: Precigen, Inc., PGEN Therapeutics, Inc.Inventors: Douglas E. BROUGH, Cheryl G. BOLINGER, Ramya YARLAGADDA, Vinodhbabu KURELLA, Ponraj PRABAKARAN, Simon METENOU, Kuan-Fu DING
-
Publication number: 20210015911Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.Type: ApplicationFiled: March 6, 2019Publication date: January 21, 2021Applicants: Precigen, Inc., PGEN Therapeutics, Inc.Inventors: Douglas E. BROUGH, Cheryl G. BOLINGER, Ramya YARLAGADDA, Vinodhbabu KURELLA, Ponraj PRABAKARAN, Simon METENOU, Kuan-Fu DING
-
Patent number: 10876137Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.Type: GrantFiled: July 13, 2017Date of Patent: December 29, 2020Assignee: PRECIGEN, INC.Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
-
Publication number: 20200283778Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.Type: ApplicationFiled: May 22, 2020Publication date: September 10, 2020Applicant: PRECIGEN, INC.Inventors: Rutul R. SHAH, Thomas D. Reed, Cheryl G. Bolinger